Merck, Modifi

Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 bln
Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday.
Merck sets sights on brain cancer with $30M Modifi acquisition
Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma.
Merck acquires Modifi Biosciences in $1.3bn cancer therapy deal
The acquisition strengthens Merck's oncology portfolio as the company looks to off the expiration of the patent for pembrolizumab.
Merck acquires Modifi Biosciences for $30M upfront
Modifi Biosciences announced that the company has been acquired by Merck (MRK). Under the terms of the agreement Merck, through a subsidiary,
Modifi Biosciences Acquired by Merck
Modifi Biosciences, Inc. ("Modifi Biosciences"), a leader in the development of direct DNA modification enabled cancer therapeutics, today announced that the company has been acquired by Merck, known as MSD outside of the United States and Canada.
Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 billion
Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday. As part of the deal, the U.S.
Merck buys Modifi for $30M plus up to $1.3B in potential payments
Merck (NYSE:MRK) has acquired Modifi Biosciences, a developer of DNA modification-enabled cancer drugs, for $30M upfront and up to $1.3B in potential milestone payments. Modifi, a spinout of Yale University,
Merck Buys Yale Cancer-Therapy Spinout Modifi Biosciences
Modifi on Wednesday said the deal gives Rahway, N.J., drugmaker Merck access to preclinical compounds designed to exploit DNA repair defects in hard-to-treat cancers, including glioblastoma, the most aggressive type of brain tumor.
Merck Keytruda cleared in EU for two new indications in gynecologic cancers
Merck’s (NYSE:MRK) blockbuster cancer therapy Keytruda (pembrolizumab) has been cleared by the European Commission to treat ...
Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers
Failed to import article template. Reason: Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app ...
Outsourcing-pharma4h
Merck acquires cancer startup in a deal worth up to $1.3 billion
Merck’s acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair ...
bovnews1h
Merck & Co Inc (MRK) Stock Settles at $106.38: What’s Contributing to This Price Point?
Bernstein has recently initiated Merck & Co Inc (MRK) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on March 11, 2024, Societe Generale had reduced the ...
Pfizer, Merck Pneumonia Shots Get Backing for Adults Over 50
A key panel of US health advisers voted in favor of lowering the age recommendation for vaccines made by Pfizer Inc. and ...
FiercePharma17h
In boon for Pfizer and Merck, CDC panel backs expanded use of pneumococcal vaccines
With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...
Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?
We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates ...
The Journal1d
Merck Animal Health introduces SENSEHUB Dairy Youngstock
Merck Animal Health, a division of Merck & Co., Inc., Rahway, New Jersey, has introduced SENSEHUB Dairy Youngstock, the ...
Business Wire3h
Merck Foundation Awarded the “NGO of the Year 2024” for Leading Community Empowerment in Africa by Voters’ Choice
Merck Foundation Awarded the “NGO of the Year 2024” for Leading Community Empowerment in Africa by Voters’ Choice ...